LOWER GWYNEDD, PA — ChromaTan, Inc., a distinguished bioprocess development firm, recently announced that it has been selected as a BLUE KNIGHT™ company. This initiative is a collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS). The initiative is dedicated to accelerating transformative technology and science that can swiftly respond to evolving public health and safety threats.
As a Blue Knight company, ChromaTan will gain access to the global JLABS ecosystem, one of the premier life science incubator programs. ChromaTan has made significant strides in bioprocessing with the development of the Kascade™ BioRMB™ platform — the first-ever columnless, single-use, steady-state continuous elution chromatography platform derived from the real moving bed technique. This innovation offers dramatic improvements in productivity and enhanced purities compared to conventional column chromatography.
ChromaTan’s President and CEO, Dr. Rajiv Datar expressed his excitement about the partnership. “We aim to empower biopharmaceutical manufacturers with transformational bioprocessing technologies that increase recoveries, enhance flexibility, scalability and purity, reduce resin consumption and downtime, and maximize productivity for the cost-effective production of life-saving therapies,” he said.
Prof. Andew Zydney, Chair of ChromaTan’s Technology Advisory Board and the Bayard D. Kunkle Chair and Professor in the Department of Chemical Engineering at Penn State University, also commented on the development. He stated, “It has been great to see the advancement of ChromaTan’s proprietary platform. I am thrilled with this acceptance and look forward to the commercial adoption of the Kascade™ BioRMB™ system in the very near future.”
ChromaTan’s Founder and Chief Technology Officer, Oleg Shinkazh, further highlighted the company’s pioneering efforts. “ChromaTan is at the forefront of a new era of integrated continuous bioprocessing that will replace traditional lengthy batched-based biopurification operations,” he noted.
ChromaTan launched its Kascade BioRMB Process Development System in September 2023. The company has been awarded FDA, NIH, and NIIMBL grants totaling more than $10 million and has raised $5 million as Series A. With Blue Knight, ChromaTan will expand its US footprint with laboratory space at JLABS @ Washington, DC, in addition to its home office & lab in Lower Gwynedd, PA.
This partnership signals a significant step for ChromaTan towards revolutionizing bioprocessing technologies, marking an important milestone.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.